Royce & Associates LP increased its position in shares of CryoPort Inc (NASDAQ:CYRX) by 60.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 220,198 shares of the consumer goods maker’s stock after purchasing an additional 82,998 shares during the period. Royce & Associates LP owned 0.78% of CryoPort worth $1,892,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Allianz Asset Management GmbH acquired a new position in shares of CryoPort during the third quarter worth $1,120,000. Vanguard Group Inc. grew its stake in shares of CryoPort by 96.9% during the second quarter. Vanguard Group Inc. now owns 519,100 shares of the consumer goods maker’s stock worth $2,554,000 after purchasing an additional 255,519 shares in the last quarter. Granite Investment Partners LLC acquired a new position in shares of CryoPort during the third quarter worth $535,000. Creative Planning acquired a new position in shares of CryoPort during the fourth quarter worth $5,176,000. Finally, Taylor Wealth Management Partners grew its stake in shares of CryoPort by 5.6% during the fourth quarter. Taylor Wealth Management Partners now owns 415,575 shares of the consumer goods maker’s stock worth $3,570,000 after purchasing an additional 21,935 shares in the last quarter. Hedge funds and other institutional investors own 22.83% of the company’s stock.
CryoPort Inc (NASDAQ:CYRX) traded down $0.40 during midday trading on Wednesday, reaching $9.68. 91,690 shares of the company’s stock traded hands, compared to its average volume of 121,261. CryoPort Inc has a one year low of $1.96 and a one year high of $10.40. The firm has a market capitalization of $268.75, a P/E ratio of -28.49 and a beta of 0.71.
CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, March 6th. The consumer goods maker reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). CryoPort had a negative net margin of 66.09% and a negative return on equity of 47.36%. The company had revenue of $3.33 million during the quarter, compared to analyst estimates of $3.37 million. The business’s revenue was up 49.5% compared to the same quarter last year. analysts forecast that CryoPort Inc will post -0.27 EPS for the current year.
A number of equities analysts recently commented on CYRX shares. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price (up previously from $10.00) on shares of CryoPort in a research note on Thursday, March 8th. Roth Capital started coverage on shares of CryoPort in a research note on Thursday, November 30th. They set a “buy” rating and a $12.50 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. CryoPort presently has a consensus rating of “Buy” and a consensus target price of $33.70.
COPYRIGHT VIOLATION WARNING: This story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/14/cryoport-inc-cyrx-stake-boosted-by-royce-associates-lp.html.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.